Loading…
for educational and safety purposes
TAK-653 and Sunifiram both come up in the same conversations; they overlap on Glutamate. TAK-653: TAK-653, also called osavampator or NBI-1065845, is an experimental oral drug that makes the brain's main excitatory receptor, the AMPA glutamate receptor, respond more strongly to glutamate the brain is already releasing; crucially it cannot switch the receptor on by itself, a design choice intended to avoid the seizure risk that stopped earlier drugs of this type. Sunifiram: Sunifiram (DM-235) is a synthetic nootropic structurally related to piracetam but dramatically more potent, active at very low doses.
TAK-653, also called osavampator or NBI-1065845, is an experimental oral drug that makes the brain's main excitatory receptor, the AMPA glutamate receptor, respond more strongly to glutamate the brain is already releasing; crucially it cannot switch the receptor on by itself, a design choice intended to avoid the seizure risk that stopped earlier drugs of this type. It is being developed as a fast-acting antidepressant for people whose depression has not responded to standard antidepressants. A 183-person Phase 2 trial found that 1 mg once daily beat placebo on a standard depression rating scale while 3 mg did not reach statistical significance, and five Phase 3 trials are now enrolling; those Phase 2 results have not yet been published in a peer-reviewed journal. It is approved nowhere in the world, it is not a legal supplement, and the entire published literature amounts to about ten papers, most of them written by employees of the companies that own it.
Sunifiram (DM-235) is a synthetic nootropic structurally related to piracetam but dramatically more potent, active at very low doses. It enhances learning and memory by acting on the glycine site of the NMDA receptor and strengthening AMPA-mediated signaling through the CaMKII and PKC pathways, the molecular basis of long-term potentiation. In animal studies it improves cognition and reverses drug-induced amnesia at doses roughly a thousandfold lower than classic racetams, making it one of the most potent research nootropics of its kind.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
positive allosteric modulator; potentiates glutamate-evoked currents only when glutamate is present, with minimal intrinsic agonism
facilitates
Off-target enzyme inhibition; the only hit in a 97-target screening panel at 10 uM
Downstream consequence of AMPA receptor potentiation, not a binding target; increased phosphorylated mTOR, p70S6K, Akt and ERK and raised BDNF protein in rat primary cortical neurons
Positive allosteric modulator; binds only in the presence of glutamate, at the intradimer interface in the channel-closed state, sterically gated by Ser750 in GluA2o (Ser743 in GluA1i)
No binding; TAK-653 does not displace [3H]-AMPA and instead mildly enhances its binding, confirming it is not an agonist
raises BDNF protein in rat primary cortical neurons and in a primate chronic-stress model
binds at the dimer interface and stabilizes the active conformation; structural interference at Ser743 is what keeps agonistic activity low
No prominent subunit selectivity across homomeric AMPA receptor subtypes
Potentiates glutamate-evoked Ca2+ influx in hGluA1i-expressing CHO cells; no effect without glutamate
increases phosphorylation in cortical neurons secondary to AMPA-R activation
Potentiates AMPA-evoked Ca2+ influx in rat primary hippocampal neurons
Potentiates AMPA-elicited whole-cell currents in rat primary hippocampal neurons
stimulates downstream
activates
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.